Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

388 NEOMYCIN
NEOMYCIN
Trade names: Cortosporin; Dexacine; Gemicina; Maxitrol
(Falcon); Myciguent; Neomicina; Neomycine Diamant; Neosporin
(Pfizer) (Monarch); Neosulf; Nivemycin; Poly-Pred
Indications: Various infections caused by susceptible organisms
Category: Antibiotic, aminoglycoside
Half-life: 3 hours
Clinically important, potentially hazardous interactions
with: aldesleukin, aminoglycosides, atracurium, bumetanide,
doxacurium, ethacrynic acid, furosemide, methoxyflurane,
pancuronium, penicillin V, polypeptide antibiotics, rocuronium,
succinylcholine, torsemide, vecuronium
Reactions
Skin
Allergic reactions (sic)
Angioedema
Bullous dermatitis
Dermatitis (1–10%)
(2006): Garcia-Rubio I+, J Investig Allergol Clin Immunol
16(4), 264
(2000): Hillen U+, Hautarzt 51, 239
(1999): Giordano-Labadie F+, Contact Dermatitis 40, 192
(2.6%) (in atopics)
(1999): Lestringant GG+, Int J Dermatol 38, 181 (5.1%)
(1998): Katsarou-Katsari A+, J Eur Acad Dermatol Venereol 11, 9
(1998): Kimura M+, Contact Dermatitis 39, 148
(1997): Dasaraju P+, Clin Infect Dis 25, 33
(1996): Sheretz EF, Arch Dermatol 132, 461
(1994): Fisher AA, Cutis 54, 300
(1993): Lipozencic J+, Arh Hig Rada Toksikol (Serbo-Croatian-
Roman) 44, 173
(1991): Barros MA+, Contact Dermatitis 25, 156
(1991): Mariani R+, Contact Dermatitis 24, 227
(1990): Bouffioux B+, Nouv Dermatol (French) 9, 25
(1990): Grandinetti PJ+, JAmAcadDermatol23, 646
(1990): Smith IM+, Clin Otolaryngol 15, 155
(1989): Guin JD+, Cutis 43, 564
(1989): Massone L+, Contact Dermatitis 21, 344
(1988): Shupp DL+, Cutis 42, 528
(1987): Abdul-Gaffoor PM, Indian J Dermatol 32, 102
(1986): Bajaj AK+, Int J Dermatol 25, 103
(1986): Baldinger J+, Ann Ophthalmol 18, 95
(1986): Rebandel P+, Contact Dermatitis 15, 92
(1985): Fisher AA, Cutis 35, 315
(1985): Fraki JE+, Acta Otolaryngol Stockh 100, 414
(1985): Frenzel U+, Phlebologie (French) 38, 389
(1985): Szarmach H+, Przegl Dermatol (Polish) 72, 521
(disseminated)
(1984): Menne T+, Hautarzt (German) 35, 319
(1983): Macdonald RH+, Clin Exp Dermatol 8, 249
(1982): Fisher AA, Ann Allergy 49, 97
(1981): Fisher AA+, Cutis 28, 491
(1981): Gordon W, SAfrMedJ 59, 212
(1981): LeRoy R+, Derm Beruf Umwelt (German) 29, 168
(1980): Epstein E, Contact Dermatitis 6, 219
Eczema
Erythema multiforme
(1986): Fisher AA, Cutis 37, 158
Exanthems
(1990): Bouffioux B+, Nouv Dermatol (French) 9, 25
Fixed eruption
(1985): Gomez B+, Allergol Immunopathol Madr (Spanish) 13, 87
Pruritus
Rash (sic) (1–10%)
Toxic epidermal necrolysis
Ulcerations
Urticaria (1–10%)
Hair
Hair – alopecia
Other
Anaphylactoid reactions/Anaphylaxis
(1986): Goh CL, Australian J Dermatol 27, 125
Hypersensitivity
(2001): Le Coz CJ, Ann Dermatol Venereol 128(12), 1359
NEPAFENAC
Trade name: Nevanac (Alcon)
Indications: Pain and inflammation associated with cataract
surgery
Category: Non-steroidal anti-inflammatory
Half-life: N/A
Clinically important, potentially hazardous interactions
with: None
Eyes
Conjunctival edema (1–5%)
Epiphora (1–5%)
Ocular hemorrhage (1–5%)
Ocular pain (1–5%)
Ocular pressure (5–10%)
Ocular pruritus (1–5%)
Photophobia (1–5%)
Vision blurred (5–10%)
NESIRITIDE
Reactions
Trade name: Natrecor (Scios)
Indications: Acutely decompensated congestive heart failure
Category: Hormone, polypeptide; Natriuretic
Half-life: 18 minutes
Reactions
Skin
Diaphoresis (>1%)
Pruritus (>1%)
Rash (sic) (>1%)
Other
Cough (>1%)
Death
(2006): Stampfli T+, Rev Med Suisse 2(50), 295
(2005): Sackner-Bernstein JD+, JAMA 293(15), 1900
Hepatotoxicity
(2006): Mallolas J, AIDS Rev 8(4), 238
Nephrotoxicity
(2006): Stampfli T+, Rev Med Suisse 2(50), 295
Phlebitis